Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.
about
Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.Alloreactivity of virus-specific T cells: possible implication of graft-versus-host disease and graft-versus-leukemia effects.Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host diseaseUltra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.Allo-reactive T cells for the treatment of hematological malignancies.Donor-specific alloreactive T cells can be quantified from whole blood, and may predict cellular rejection after renal transplantation.Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.Activation-induced CD137 is a fast assay for identification and multi-parameter flow cytometric analysis of alloreactive T cells.HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia.Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line.Low-dose donor memory T-cell infusion after TCR alpha/beta depleted unrelated and haploidentical transplantation: results of a pilot trial.Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype.Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.
P2860
Q35094029-55B28502-7739-47E0-98D0-E4EC2F6FCC2DQ35591430-4E7E5E8D-2176-4274-BF52-0AD45F49E425Q37229016-DD1E0B3B-D13E-409C-BB42-2829D099992EQ37383856-F4617ECC-1CE1-4425-8731-78A7513125C3Q37707135-BF0EA907-6EDC-4E04-BAC6-564B27C0B9C7Q38636565-AD5046DF-2E99-473F-9573-E1537A37DA4DQ40244185-9935A219-2F0E-4CE5-8F39-651A473C0450Q40657274-16F5DCFD-5202-46B5-B9F8-5A8A50FA3FA8Q40832630-28EC6D61-7AF5-408B-89BC-7D165365EF36Q43606110-08D56DD4-ABD8-43F7-8363-31D648B1DE03Q46626736-C39C1D4D-BF7E-46E6-A17C-A8B0B8E44F47Q47548299-866E3527-D4E1-46F4-A397-A99966AC9F77Q48362228-25B1E0C9-E3EE-419D-A030-05630549E2D3Q50098673-24207F3A-B20E-4CB8-9E6D-25162DCE99A0Q53652856-67BE8B81-28CE-4B3F-92F0-BA4D15A531EE
P2860
Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Alloreactivity across HLA barr ...... d antigen-experienced T cells.
@ast
Alloreactivity across HLA barr ...... d antigen-experienced T cells.
@en
type
label
Alloreactivity across HLA barr ...... d antigen-experienced T cells.
@ast
Alloreactivity across HLA barr ...... d antigen-experienced T cells.
@en
prefLabel
Alloreactivity across HLA barr ...... d antigen-experienced T cells.
@ast
Alloreactivity across HLA barr ...... d antigen-experienced T cells.
@en
P2093
P2860
P1476
Alloreactivity across HLA barr ...... nd antigen-experienced T cells
@en
P2093
A John Barrett
Ann Williams
Daniel C Douek
David R Ambrozak
J Joseph Melenhorst
J Philip McCoy
Keyvan Keyvanfar
Melody Smith
Nancy F Hensel
P2860
P304
P356
10.1016/J.BBMT.2010.12.711
P577
2011-01-06T00:00:00Z